Inhaled Mucomyst (Acetylcysteine) Dosing for Chest Congestion

Clinical Context and Evidence Quality

• The Cystic Fibrosis Foundation found insufficient evidence to recommend for or against chronic inhaled N-acetylcysteine in patients with cystic fibrosis, with no demonstrated clinical benefit or improvement in lung function, as reported by the American Journal of Respiratory and Critical Care Medicine 1, 2
• The European Respiratory Society suggests oral mucolytic therapy for patients with moderate to severe COPD and exacerbations despite optimal inhaled therapy, with high-dose oral therapy showing greater efficacy 3, 4